A Phase III, Randomized, Double Blind, Placebo Controlled, Multicentre Study ofMaintenance Olaparib Monotherapy in Patients with gBRCA Mutated MetastaticPancreatic Cancer whose Disease Has Not Progressed on First Line Platinum BasedChemotherapy
Sponsor: |
AstraZeneca |
Enrolling: |
Male and Female Patients |
IRB Number: |
AAAO2705 |
U.S. Govt. ID: |
NCT02184195 |
Contact: |
Paul Oberstein: 646-317-6085 / p02178@cumc.columbia.edu |
This research study is being conducted to see if a new treatment using a study drug called Olaparib given after platinum based chemotherapy treatments can reduce the risk of pancreatic cancer from growing back. Participants will receive either Olaparib or placebo (no contains active medication) and will stay on the research study for as long as they are not getting worse.
This study is closed
Investigator
Paul Oberstein, MD
Do you have a diagnosis of pancreatic adenocarcinoma? |
Yes |
No |